CLINICAL_TRIALS
trial_result
· 2021-08-02
Clinical Trial Update: Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas [Phase 2]
Summary
Phase 2 trial evaluating selinexor (KPT-330) in recurrent gliomas was terminated; results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Karyopharm Therapeutics Inc | Conditions: Glioblastoma, Glioma | Phase 2 | Status: TERMINATED | Results posted: 2021-08-02